Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

  • End date
    Jan 20, 2036
  • participants needed
  • sponsor
    Institut Curie
Updated on 13 April 2021
Primary Contact
CHU ESTAING Centre R gional de Canc rologie et Therapie Cellulaire Pediatrique (CRCTCP) (2.1 mi away) Contact
+27 other location


This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients:

  • Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
  • Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic treatments.


Primary objective of the studies:

  • Study 1: To evaluate the efficacy of IAC in term of local control of the disease in patients eligible for IAC (randomized phase II study);
  • Study 2: To assess the visual function, based on World Health Organization (WHO) criteria, in patients eligible for other conservative treatments (IV chemotherapy in association with local ophthalmologic treatments; this is a minimally invasive interventional study).

Condition Retinoblastoma
Treatment Melphalan or Melphalan + Topotecan, etoposide, carboplatin and vincristine, Carboplatin administered on Day 1, Thermotherapy (local treatment), Cryotherapy (local treatment), Iodine-125 plaques (local treatment), Intravitreal Melphalan chemotherapy injections (local treatment)
Clinical Study IdentifierNCT04681417
SponsorInstitut Curie
Last Modified on13 April 2021


Yes No Not Sure

Inclusion Criteria

RB not eligible for conservative management
Extra-ocular extension of the disease, or
Group E eyes with invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye
Patient older than 6 years of age
Patients with another associated disease contra indicating systemic chemotherapy
Previously treated retinoblastoma by chemotherapy
Patients already treated for another malignant disease
Patient with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Patients whose parents have not accepted the treatment regimen after explanation of it
Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics) of the study drugs
Inclusion in another experimental anti-cancer drug therapy
Study 1 non-inclusion criteria
\. Any contraindication or concomitant disease that would preclude the Study
treatment procedure and could delay treatment
These patients should be eligible for Study 2
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note